Drugs / bucindolol
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01970501 | Apr 2014 → Dec 2017 | atrial fibrillation | ARCA Biopharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00000560 | Jun 1994 → Sep 1999 | congestive heart failure | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bucindolol | “Bucindolol is a β-blocker/sympatholytic agent whose efficacy is modulated by polymorphisms in the primary target (β(1) adrenergic receptor [AR] Arg389 Gly on cardiac myocytes)...” PMID 23071495 ↗ Oct 2012 |
| Known as | Bucindolol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL321582 ↗ |
| Known as | bucindolol hydrochloride | “bucindolol hydrochloride (bucindolol)” NCT01970501 ↗ |
| Known as | Gencaro | ChEMBL registry synonym — accepted as the source's own label CHEMBL321582 ↗ |
| Known as | MJ 13,105-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL321582 ↗ |
| Action | Inhibit | “Beta-1 adrenergic receptor antagonist” CHEMBL321582 ↗1“Beta-2 adrenergic receptor antagonist” CHEMBL321582 ↗ |
| Modality | Small molecule | — CHEMBL321582 ↗ |
| Route | Oral | “Capsules for titration were available in the following dosage strengths to be taken twice daily” NCT01970501 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL321582 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL321582 ↗ |